The UK’s medicine regulatory authority recently approved elinzanetant for management of moderate to severe hot flashes associated with menopause and decreasing ovarian function. Elinzanetant is an antagonist of both neurokinin (NK) -1 and -3 receptors. The NK-3 receptor has been well-described in the aetiology of hot flashes (overexpression of neurokinin B and substance P disrupts thermoregulation) and the NK-1 receptor is also hypothesized to play a role in peripheral vasodilatation and primary insomnia.

Read more here.